Why the study?
Racial and ethnic disparities persist in type 2 diabetes care, and this study examined whether blood glucose differences vary by race/ethnicity among digital therapeutic platform users over a year.
Does a digital therapeutic platform improve blood glucose levels across different racial and ethnic groups in high-risk patients with type 2 diabetes?
Does a digital therapeutic platform improve blood glucose levels across different racial and ethnic groups in high-risk patients with type 2 diabetes?
A digital therapeutic platform significantly reduced average blood glucose levels over one year in high-risk type 2 diabetes patients, with similar improvements observed across different racial and ethnic groups.
No takes yet. Share an insight, caveat, or question.
No racial/ethnic differences in glycemic improvement among digital platform users; leaves open equitable access effects beyond engaged cohorts.
HERSHCOVITZ et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: